Marivet

Description

Maviret is intended for the treatment of chronic hepatitis C in adults and children over 12 years of age.

The drug Maviret is a combination of two pangenotypic direct-acting antiviral agents in fixed doses – glecaprsvir and pibrentasvir, affecting various stages of the life cycle of the hepatitis C virus of all major genotypes.

Active ingredients: glecaprsvir and pibrentasvir

Prescription medicine